Aliases & Classifications for Retinitis

MalaCards integrated aliases for Retinitis:

Name: Retinitis 12 56 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3612
MeSH 45 D012173
NCIt 51 C115993
SNOMED-CT 69 35426003
ICD10 34 H30.9
UMLS 74 C0035333

Summaries for Retinitis

MalaCards based summary : Retinitis is related to retinitis pigmentosa 2 and retinitis pigmentosa 28. An important gene associated with Retinitis is RPGR (Retinitis Pigmentosa GTPase Regulator). The drugs Ganciclovir and Cidofovir have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone, and related phenotypes are nervous system and vision/eye

Related Diseases for Retinitis

Diseases related to Retinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1882)
# Related Disease Score Top Affiliating Genes
1 retinitis pigmentosa 2 34.1 RP2 RPGR
2 retinitis pigmentosa 28 33.9 FAM161A FLVCR1
3 retinitis pigmentosa 6 33.7 RHO RP9
4 retinitis pigmentosa 25 33.7 EYS RP9
5 retinitis pigmentosa 7 33.7 PRPH2 RHO RP9
6 retinitis pigmentosa 9 33.7 IMPDH1 RP9
7 retinitis pigmentosa 1 33.6 PRPH2 RHO RP1 RP1L1
8 retinitis pigmentosa 10 33.5 IMPDH1 RHO RP9
9 peripheral retinal degeneration 33.5 PRPH2 RPGR
10 fundus albipunctatus 33.4 PRPH2 RHO RLBP1
11 retinal degeneration 33.3 PRPH2 RHO RLBP1 RP2 RPGR RPGRIP1
12 retinitis pigmentosa 18 33.2 IMPDH1 PRPF3 RP9
13 retinitis pigmentosa 13 33.1 IMPDH1 PRPF3 RP9 RPGR
14 cone-rod dystrophy 2 32.8 CERKL FAM161A PRPH2 RHO RPGR RPGRIP1
15 cone dystrophy 32.6 RHO RLBP1 RPGR
16 retinal disease 32.6 IMPDH1 PRPF3 PRPH2 RHO RLBP1 RPGR
17 leber congenital amaurosis 32.4 IMPDH1 PRPH2 RHO RP2 RPGR RPGRIP1
18 bestrophinopathy 32.3 PRPH2 RLBP1
19 stargardt disease 32.2 EYS PRPH2 RHO RPGR
20 usher syndrome, type iid 32.1 RHO RPGR
21 laurence-moon syndrome 31.1 RPGR RPGRIP1
22 fundus dystrophy 30.7 ABHD12 CERKL EYS PRPH2 RHO RLBP1
23 stargardt macular degeneration 29.9 PRPH2 RHO
24 retinitis pigmentosa 28.8 ABHD12 CERKL EYS FAM161A FLVCR1 IMPDH1
25 retinal detachment 12.5
26 retinitis pigmentosa 3 12.5
27 retinitis pigmentosa 27 12.4
28 retinitis pigmentosa 12 12.4
29 doyne honeycomb retinal dystrophy 12.4
30 central retinal vein occlusion 12.4
31 retinitis pigmentosa 11 12.4
32 retinitis pigmentosa 4 12.4
33 retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities 12.4
34 retinitis pigmentosa 17 12.4
35 retinitis pigmentosa 30 12.4
36 late-onset retinal degeneration 12.4
37 retinitis pigmentosa 51 12.4
38 retinitis pigmentosa 55 12.4
39 retinitis pigmentosa 45 12.4
40 cytomegalovirus retinitis 12.3
41 retinal vascular occlusion 12.3
42 central retinal artery occlusion 12.3
43 neuropathy, ataxia, and retinitis pigmentosa 12.3
44 infantile cerebellar-retinal degeneration 12.3
45 retinitis pigmentosa 50 12.3
46 posterior column ataxia with retinitis pigmentosa 12.3
47 retinal arteries, tortuosity of 12.3
48 retinitis pigmentosa 41 12.3
49 retinitis pigmentosa 67 12.3
50 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 12.3

Graphical network of the top 20 diseases related to Retinitis:



Diseases related to Retinitis

Symptoms & Phenotypes for Retinitis

MGI Mouse Phenotypes related to Retinitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.9 ABHD12 FAM161A PRPH2 RHO RLBP1 RP1
2 vision/eye MP:0005391 9.47 ABHD12 CERKL FAM161A IMPDH1 PRPF3 PRPH2
3 pigmentation MP:0001186 9.43 PRPF3 PRPH2 RHO RLBP1 RPGR SEMA4A

Drugs & Therapeutics for Retinitis

Drugs for Retinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454
2
Cidofovir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113852-37-2 60613
3
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 63585-09-1, 4428-95-9 3415
4
Probenecid Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57-66-9 4911
5
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4408-78-0 546
6 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Renal Agents Phase 4,Phase 2,Phase 1,Not Applicable
14
Valganciclovir Approved, Investigational Phase 3,Phase 2,Not Applicable 175865-60-8 64147
15
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
16
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
17
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
18
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
21
Sulfadiazine Approved, Investigational, Vet_approved Phase 3 68-35-9 5215
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
23
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
25
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
26
Sargramostim Approved, Investigational Phase 3,Not Applicable 123774-72-1, 83869-56-1
27
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
28
Acyclovir Approved Phase 3,Not Applicable 59277-89-3 2022
29
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2,Early Phase 1 59-30-3 6037
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
32
Lutein Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 127-40-2 6433159
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3,Phase 1 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
34
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
35
Beta carotene Approved, Nutraceutical Phase 2, Phase 3,Phase 1 7235-40-7
36
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
37 Tocotrienol Investigational Phase 3 6829-55-6
38 Hormone Antagonists Phase 2, Phase 3,Phase 3,Phase 1
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3,Phase 1
40 Antihypertensive Agents Phase 2, Phase 3,Phase 3,Phase 1
41 diuretics Phase 2, Phase 3,Phase 1
42 Diuretics, Potassium Sparing Phase 2, Phase 3,Phase 1
43 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3,Phase 1
44 Hormones Phase 2, Phase 3,Phase 3,Phase 1
45 Natriuretic Agents Phase 2, Phase 3,Phase 1
46 Mineralocorticoids Phase 2, Phase 3,Phase 1
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
48 HIV Protease Inhibitors Phase 3,Phase 2
49 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2,Not Applicable
50 Anti-Inflammatory Agents Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
2 The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction Completed NCT00717080 Phase 4
3 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
4 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
5 Use of Cidofovir for Recurrent Respiratory Papillomatosis Completed NCT00205374 Phase 4 Cidofovir;Placebo
6 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3 Valganciclovir
7 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
8 To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis Unknown status NCT00372294 Phase 3 pyrimethamine-sulfadiazine + prednisolone;Clindamycin+Dexamethasone
9 Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A Completed NCT00346333 Phase 3 Lutein
10 Randomized Trial for Retinitis Pigmentosa Completed NCT00000116 Phase 3 Vitamin A;Nutritional Supplement
11 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed NCT00000142 Phase 2, Phase 3 Cidofovir
12 Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed NCT00000135 Phase 2, Phase 3 MSL-109
13 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
14 Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed NCT00000134 Phase 3 Ganciclovir;Foscarnet
15 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
16 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
17 Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT) Completed NCT00000136 Phase 3 Foscarnet;Ganciclovir
18 Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa Completed NCT00000114 Phase 3 Vitamin E;Vitamin A
19 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000143 Phase 3 Cidofovir intravenous
20 Ganciclovir Implant Study for Cytomegalovirus Retinitis Completed NCT00000118 Phase 3
21 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed NCT00002377 Phase 3 Valganciclovir;Ganciclovir
22 Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
23 Ozurdex for Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3 Dexamethasone;dexamethasone
24 Laser and Medical Treatment of Diabetic Macular Edema Completed NCT00050479 Phase 3 Celecoxib (Celebrex)
25 Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Completed NCT02137772 Phase 3 Letermovir;Placebo
26 A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Recruiting NCT03116113 Phase 2, Phase 3
27 The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Recruiting NCT01680510 Phase 2, Phase 3
28 Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity Recruiting NCT03746522 Phase 3 Setmelanotide;Placebos
29 Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity Recruiting NCT03013543 Phase 2, Phase 3 Setmelanotide
30 Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis Active, not recruiting NCT00999609 Phase 3
31 Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome Enrolling by invitation NCT03184584 Phase 2, Phase 3 PBI-4050
32 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes Not yet recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
33 Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa Terminated NCT01786395 Phase 3 UF-021;Placebo
34 Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study Unknown status NCT02661711 Phase 2 Aflibercept
35 Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Unknown status NCT01914913 Phase 1, Phase 2
36 Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study Unknown status NCT02804360 Phase 2
37 Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa Completed NCT01560715 Phase 2
38 Trial of Oral Valproic Acid for Retinitis Pigmentosa Completed NCT01233609 Phase 2 Valproic Acid;Placebo
39 Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa Completed NCT02140164 Phase 1, Phase 2 Minocycline
40 A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa Completed NCT00447993 Phase 2 NT-501;NT-501
41 Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa Completed NCT02320812 Phase 1, Phase 2
42 Safety Study in Retinal Transplantation for Retinitis Pigmentosa. Completed NCT00345917 Phase 2
43 A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa Completed NCT00447980 Phase 2 NT-501;NT-501
44 CMV Retinitis Retreatment Trial Completed NCT00000766 Phase 2 Foscarnet sodium;Ganciclovir
45 Effects of Lutein in Retinitis Pigmentosa Completed NCT00029289 Phase 1, Phase 2 Lutein (10 or 30 mg/day) capsules
46 Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema Completed NCT02609165 Phase 2 rhNGF 180 µg/ml eye drops solution;vehicle eye drops
47 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Completed NCT00002156 Phase 2 Fomivirsen sodium;Ganciclovir
48 A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis Completed NCT00002169 Phase 2 Nelfinavir mesylate
49 DHA and X-Linked Retinitis Pigmentosa Completed NCT00100230 Phase 2 docosahexaenoic acid OR corn/soy oil placebo
50 A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure Completed NCT00000691 Phase 2 Foscarnet sodium

Search NIH Clinical Center for Retinitis

Genetic Tests for Retinitis

Anatomical Context for Retinitis

MalaCards organs/tissues related to Retinitis:

42
Eye, Retina, Bone, Testes, Bone Marrow, T Cells, Endothelial

Publications for Retinitis

Articles related to Retinitis:

(show top 50) (show all 4511)
# Title Authors Year
1
CD4+ cells as a potential biomarker for cytomegalovirus retinitis in children with acute lymphocytic leukemia. ( 30681505 )
2019
2
Active cytomegalovirus retinitis after the start of antiretroviral therapy. ( 30196272 )
2019
3
Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. ( 30642941 )
2019
4
A cross-sectional study of cytomegalovirus retinitis in HIV-1 infected adults in Nigeria. ( 30837414 )
2019
5
Concurrent cerebral toxoplasmosis and cytomegalovirus retinitis in a patient with human immunodeficiency virus. ( 30851795 )
2019
6
Phenotypic spectrum of autosomal recessive retinitis pigmentosa without posterior column ataxia caused by mutations in the FLVCR1 gene. ( 30656474 )
2019
7
A novel splicing mutation in the PRPH2 gene causes autosomal dominant retinitis pigmentosa in a Chinese pedigree. ( 30892800 )
2019
8
Correlation between Visual Function and Structural Characteristics of the Macula in Advanced Retinitis Pigmentosa. ( 30893682 )
2019
9
Concentric Choriocapillaris Flow Deficits in Retinitis Pigmentosa Detected Using Wide-Angle Swept-Source Optical Coherence Tomography Angiography. ( 30897619 )
2019
10
Genomic landscape of sporadic retinitis pigmentosa: findings from 877 Spanish cases. ( 30902645 )
2019
11
Altered intra- and inter-regional functional connectivity of the visual cortex in individuals with peripheral vision loss due to retinitis pigmentosa. ( 30904614 )
2019
12
Natural models for retinitis pigmentosa: progressive retinal atrophy in dog breeds. ( 30904946 )
2019
13
Metipranolol promotes structure and function of retinal photoreceptors in the rd10 mouse model of human retinitis pigmentosa. ( 30315650 )
2019
14
Drosophila melanogaster: A Valuable Genetic Model Organism to Elucidate the Biology of Retinitis Pigmentosa. ( 30324448 )
2019
15
SCAPER-associated nonsyndromic autosomal recessive retinitis pigmentosa. ( 30561111 )
2019
16
Role of oxidative stress in Retinitis pigmentosa: new involved pathways by an RNA-Seq analysis. ( 30569795 )
2019
17
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN PATIENTS WITH RETINITIS PIGMENTOSA. ( 30570620 )
2019
18
Simultaneous presentation of ocular surface squamous neoplasia with viral retinitis in HIV-positive patients with low CD4 counts. ( 30574905 )
2019
19
Retinitis Pigmentosa: Review of Current Treatment. ( 30585930 )
2019
20
Night-vision aid using see-through display for patients with retinitis pigmentosa. ( 30604110 )
2019
21
Clinical findings of end-stage retinitis pigmentosa with a homozygous PDE6A variant (p.R653X). ( 30619975 )
2019
22
Fundus autofluorescence and ellipsoid zone (EZ) line width can be an outcome measurement in RHO-associated autosomal dominant retinitis pigmentosa. ( 30635721 )
2019
23
Novel PDE6B Mutation Presenting with Retinitis Pigmentosa - A Case Series of Three Patients. ( 30646425 )
2019
24
A Novel CNGA1 Gene Mutation (c.G622A) of Autosomal Recessive Retinitis Pigmentosa Leads to the CNGA1 Protein Reduction on Membrane. ( 30652268 )
2019
25
Valproic acid's effects on visual acuity in retinitis pigmentosa: a systemic review and Meta-analysis. ( 30662852 )
2019
26
Optical coherence tomography angiography features of retinitis post-rickettsial fever. ( 30672502 )
2019
27
Establishment and characterization of an iPSC line (FRIMOi001-A) derived from a retinitis pigmentosa patient carrying PDE6A mutations. ( 30685614 )
2019
28
Generation of an induced pluripotent stem cell line (FRIMOi002-A) from a retinitis pigmentosa patient carrying compound heterozygous mutations in USH2A gene. ( 30685615 )
2019
29
Classification of disease severity in retinitis pigmentosa. ( 30705041 )
2019
30
Optical Coherence Tomography Angiography of RPGR-Associated Retinitis Pigmentosa Suggests Foveal Avascular Zone is a Biomarker for Vision Loss. ( 30768229 )
2019
31
Correction: Novel PDE6B Mutation Presenting with Retinitis Pigmentosa - A Case Series of Three Patients. ( 30769346 )
2019
32
A Novel Method for the Objective Identification of Hyperautofluorescent Ring in Retinitis Pigmentosa Using Binarization Processing. ( 30775157 )
2019
33
Targeted next generation sequencing identified novel loss-of-function mutations in MERTK gene in Chinese patients with retinitis pigmentosa. ( 30790467 )
2019
34
Whole exome sequencing reveals novel EYS mutations in Chinese patients with autosomal recessive retinitis pigmentosa. ( 30804660 )
2019
35
Novel stem cell and gene therapy in diabetic retinopathy, age related macular degeneration, and retinitis pigmentosa. ( 30805203 )
2019
36
A novel intronic mutation of PDE6B is a major cause of autosomal recessive retinitis pigmentosa among Caucasus Jews. ( 30820151 )
2019
37
Electrophysiological Changes During Early Steps of Retinitis Pigmentosa. ( 30840038 )
2019
38
Projection-Resolved Optical Coherence Tomographic Angiography of Retinal Plexuses in Retinitis Pigmentosa. ( 30849344 )
2019
39
Viral retinitis: diagnosis and management in the era of biologic immunosuppression - a review. ( 30859706 )
2019
40
Delay of cone degeneration in retinitis pigmentosa using a 12-month treatment with Lycium barbarum supplement. ( 30877066 )
2019
41
Novel ophthalmic formulation of myriocin: implications in retinitis pigmentosa. ( 30883241 )
2019
42
Photoreceptor cell replacement in macular degeneration and retinitis pigmentosa: A pluripotent stem cell-based approach. ( 30885665 )
2019
43
Broad spectrum metabolomics for detection of abnormal metabolic pathways in a mouse model for retinitis pigmentosa. ( 30885711 )
2019
44
The clinical application of preimplantation genetic diagnosis for X-linked retinitis pigmentosa. ( 30887160 )
2019
45
Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors. ( 29706600 )
2019
46
Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. ( 29947567 )
2018
47
Spectral domain optical coherence tomography and fundus autofluorescence findings in cytomegalovirus retinitis in HIV-infected patients. ( 29445945 )
2018
48
Characterization of Retinitis Pigmentosa Using Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO). ( 29946494 )
2018
49
Comparison of 5-year progression of retinitis pigmentosa involving the posterior pole among siblings by means of SD-OCT: a retrospective study. ( 29940899 )
2018
50
Quantification of Macular Microvascular Changes in Patients With Retinitis Pigmentosa Using Optical Coherence Tomography Angiography. ( 29365150 )
2018

Variations for Retinitis

Expression for Retinitis

Search GEO for disease gene expression data for Retinitis.

Pathways for Retinitis

GO Terms for Retinitis

Cellular components related to Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.91 FAM161A RHO RP1 RP1L1 RP2 RPGR
2 cilium GO:0005929 9.73 FAM161A RP1 RP1L1 RP2 RPGR RPGRIP1
3 ciliary basal body GO:0036064 9.62 FAM161A RP2 RPGR TOPORS
4 axoneme GO:0005930 9.58 RP1 RP1L1 RPGRIP1
5 photoreceptor inner segment GO:0001917 9.46 CERKL FAM161A RHO RP1
6 photoreceptor connecting cilium GO:0032391 9.35 FAM161A RP1 RP1L1 RPGRIP1 TOPORS
7 photoreceptor outer segment GO:0001750 9.1 CERKL PRPH2 RHO RP1 RP1L1 RPGR

Biological processes related to Retinitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.76 EYS FAM161A RHO RLBP1 RP1 RP1L1
2 cell projection organization GO:0030030 9.67 FAM161A RP1 RP1L1 RPGR
3 axoneme assembly GO:0035082 9.51 RP1 RP1L1
4 cellular response to light stimulus GO:0071482 9.49 RHO RP1
5 photoreceptor cell outer segment organization GO:0035845 9.48 RP1 TOPORS
6 retinal cone cell development GO:0046549 9.46 RP1 TOPORS
7 retinal rod cell development GO:0046548 9.43 RP1 TOPORS
8 photoreceptor cell maintenance GO:0045494 9.43 RHO RP1 RP1L1
9 phototransduction, visible light GO:0007603 9.4 RHO RP1
10 retina development in camera-type eye GO:0060041 9.35 PRPH2 RHO RP1 RP1L1 RPGRIP1
11 photoreceptor cell development GO:0042461 9.32 RP1 RP1L1
12 visual perception GO:0007601 9.32 EYS FAM161A PRPH2 RHO RLBP1 RP1

Molecular functions related to Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 11-cis retinal binding GO:0005502 8.62 RHO RLBP1

Sources for Retinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....